iData Insights

Haemophilus influenzae Type B Infections - Pipeline Review, H2 2015 Is Released

Press Release   •   Jan 27, 2016 16:23 IST

Haemophilus influenzae Type B Infections - Pipeline Review, H2 2015 Summary Global Markets Direct s, Haemophilus influenzae Type B Infections - Pipeline Review, H2 2015 , provides an overview of the Haemophilus influenzae Type B Infections s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Haemophilus influenzae Type B Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Haemophilus influenzae Type B Infections and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Haemophilus influenzae Type B Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Haemophilus influenzae Type B Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Haemophilus influenzae Type B Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Haemophilus influenzae Type B Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Haemophilus influenzae Type B Infections - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Haemophilus influenzae Type B Infections pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Browsewith TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173376/haemophilus-influenzae-type-b-infections-pipeline-review-h2-2015

To Get Sample Copy of Report visit @http://www.idatainsights.com/reports-landing-page.php?id=173376/haemophilus-influenzae-type-b-infections-pipeline-review-h2-2015

Table of Contents

Introduction 7

Global Markets Direct Report Coverage 7

Haemophilus influenzae Type B Infections Overview 8

Therapeutics Development 9

Pipeline Products for Haemophilus influenzae Type B Infections - Overview 9

Pipeline Products for Haemophilus influenzae Type B Infections - Comparative Analysis 10

Haemophilus influenzae Type B Infections - Therapeutics under Development by Companies 11

Haemophilus influenzae Type B Infections - Therapeutics under Investigation by Universities/Institutes 12

Haemophilus influenzae Type B Infections - Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Haemophilus influenzae Type B Infections - Products under Development by Companies 16

Haemophilus influenzae Type B Infections - Products under Investigation by Universities/Institutes 17

Haemophilus influenzae Type B Infections - Companies Involved in Therapeutics Development 18

Beijing Minhai Biotechnology Co., Ltd 18

Biological E. Limited 19

CSL Limited 20

Daiichi Sankyo Company, Limited 21

Indian Immunologicals Limited 22

LG Life Science LTD. 23

Nuron Biotech, Inc. (Inactive) 24

Panacea Biotec Limited 25

Sanofi Pasteur SA 26

Sinovac Biotech Ltd. 27

Zydus Cadila Healthcare Limited 28

Haemophilus influenzae Type B Infections - Therapeutics Assessment 29

Assessment by Monotherapy Products 29

Assessment by Combination Products 30

Assessment by Target 31

Assessment by Route of Administration 33

Assessment by Molecule Type 35

Drug Profiles 37

(diphtheria + pertussis (wholl cell) + tetanus + hepatitis B + Haemophilus influenza [serotype B]) (pentavalent) vaccine - Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

(diphtheria + tetanus + pertussis (acellular) + Haemophilus influenza [serotype B] + polio) vaccine - Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

(diphtheria + tetanus + pertussis (acellular) + Haemophilus influenza [serotype B]) vaccine - Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

(diphtheria + tetanus + pertussis (whole cell) + Haemophilus influenzae [serotype B] + polio) (pentavalent) vaccine - Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

(diphtheria + tetanus + pertussis (whole cell) + hepatitis B + poliomyelitis + Haemophilus influenzae [serotype B]) (hexavalent) vaccine - Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

(diphtheria + tetanus + pertussis (whole-cell) + Haemophilus influenzae [serotype B]) vaccine - Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

(diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + Haemophilus influenzae [serotype B]) (pentavalent) vaccine - Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

(diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + Haemophilus influenzae [serotype B]) vaccine - Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

(diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C]) (7-valent) vaccine - Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

(diphtheria + tetanus+ pertussis (whole cell) + hepatitis B + Haemophilus influenzae [serotype B]) (pentavalent) vaccine - Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

haemophilus influenza [serotype B] vaccine - Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

haemophilus influenzae [serotype B] vaccine - Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

haemophilus influenzae [serotype B] vaccine - Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

haemophilus influenzae [serotype B] vaccine - Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

haemophilus influenzae [serotype B] vaccine - Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

NU-300 - Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

PR-5I - Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

VN-0105 - Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Haemophilus influenzae Type B Infections - Recent Pipeline Updates 56

Haemophilus influenzae Type B Infections - Dormant Projects 58

Haemophilus influenzae Type B Infections - Product Development Milestones 59

Featured News & Press Releases 59

Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur s Investigational Pediatric Hexavalent Vaccine 59

Sep 26, 2013: Takeda Submits New Drug Application in Japan for TAK-816, a Haemophilus Influenzae type b vaccine 60

Appendix 61

Methodology 61

Coverage 61

Secondary Research 61

Primary Research 61

Expert Panel Validation 61

Contact Us 61

Disclaimer 62

Read More http://www.idatainsights.com/reports-landing-page.php?id=173376/haemophilus-influenzae-type-b-infections-pipeline-review-h2-2015

About Us:

iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.

ContactUs:
iData Insights

Tel: 1-866-237-2965

Web: http://www.idatainsights.com
Email: info@idatainsights.com

AboutiData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects